Navigation Links
Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis
Date:9/3/2008

found after the first month and a further improvement is seen after two months, where values are significantly different to the placebo group. This study again showed that patients required significantly less analgesic medication while supplementing with Pycnogenol(R), whereas this was not the case with the placebo-treated control group."

The study was held at Slovakia's Comenius University School of Medicine. One hundred patients with stage I or II OA were included in the study and were randomly allocated to either a Pycnogenol(R) or placebo group. Patients were supplemented with 150 mg Pycnogenol(R) or placebo per day over a period of three months. They were allowed to continue taking their NSAID or analgesics prescribed before the study but had to record every pill taken. The established Western Ontario McMaster questionnaire for joint function was employed to rate the pain level, and obtain measures of joint stiffness and to what extent the arthritis affects participation in daily activities. Patients were investigated in two week intervals over the treatment period of three months and a final time two weeks after discontinuation of medication.

The overall score, summarizing pain, stiffness and daily activities, improved statistical significantly by 20.9 percent in the Pycnogenol(R) group. Interestingly, the joint improvement achieved with Pycnogenol persisted after intake of Pycnogenol was discontinued for four weeks. The joint pain decreased by 40.3 percent after completion of the three months supplementation with Pycnogenol and two weeks later the pain was still 36.1 percent lower than at baseline. Furthermore, 38 percent of patients in the Pycnogenol(R) group required less NSAID's or other analgesic medication for joint pain.

"The anti-inflammatory potency of Pycnogenol(R) explains the success in lowering joint pain and stiffness for arthritic joints," said Rohdewald. "After three recent clinical studies on osteoarthritis, Pycnogenol(R)
'/>"/>

SOURCE Natural Health Science Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
2. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
3. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
4. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
5. Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First Real World, All Comers Clinical Study
6. American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast
7. Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel
8. Variant of Mad Cow Disease May Be Transmitted by Blood Transfusions, According to Animal Study
9. National Study Shows Magnesium Sulfate Reduces Risk of Cerebral Palsy in Premature Births
10. Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber
11. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  IRIDEX Corporation (NASDAQ: IRIX ... quarter 2014 financial results after the market closes on ... the release, the Company will host a conference call ... Time on Thursday, July 31, 2014 ... business developments. Interested parties may access the ...
(Date:7/24/2014)... and MENLO PARK, Calif. , July 24, ... ("DelMar" "the company") announced today that the company,s board of ... December 31 to June 30. Accordingly, DelMar will file a ... Jeffrey Bacha , president and CEO of DelMar ... step in achieving our goal of obtaining a senior exchange ...
(Date:7/24/2014)...  Kinex Pharmaceuticals announced the receipt of an allowance ... for the commencement of a Phase I clinical study ... to be allowed by the US FDA in the ... orally active and highly selective inhibitor of Src tyrosine ... of p53, G2/M arrest of proliferating cell populations and ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4
... invivodata inc., the ... and services for global clinical research, today announced ... provide the EXAcerbations of Chronic pulmonary disease Tool ... is a Patient-Reported Outcome (PRO) measure for evaluating ...
... testing in humans watershed moment for unique malaria ... a move that highlights the strength of public-private ... company Sanaria Inc., with support from the PATH ... 1 clinical trial -- the first tests in ...
Cached Medicine Technology:invivodata Certified to Deliver EXACT in COPD Trials 2invivodata Certified to Deliver EXACT in COPD Trials 3Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin 2Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin 3Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin 4
(Date:7/25/2014)... Texas (PRWEB) July 25, 2014 Yisrayl Hawkins, ... Texas, is once again stirring the pot by revealing to ... they are deceived into worshipping Satan, the devil, in his ... clever plan organized by Satan, and carried out by the ... of the Creator from the Inspired Holy Scriptures and replacing ...
(Date:7/25/2014)... 2014 According to the Liver ... by Vkool.com, this is a comprehensive guide that ... and safe remedies for liver cirrhosis . ...     Chapter 1: Liver Cirrhosis Bible ... Learn About Liver Basics ,     Chapter 3: ...
(Date:7/24/2014)... July 25, 2014 iFitDress.com, a renowned ... new range of casual party dresses . According ... party gowns are now offered at discounted prices, up ... this morning until August 04. , Most of ... in the global market. They are popular for special ...
(Date:7/24/2014)... nighttime production of the hormone melatonin, renders breast cancer ... drug, says a new study by Tulane University School ... Disruption by Exposure to Light at Night Drives Intrinsic ... the journal Cancer Research , is the first ... of tamoxifen in treating breast cancer. , , Principal ...
(Date:7/24/2014)... The report, “Content Delivery Networks (CDN) Market”, ... sub-segments with an in-depth analysis and forecasting of ... for this market with insights on trends, opportunities, ... and 36 figures spread through 157 pages and ... at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . , Early buyers ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Says You Have Been Tricked Into Worshipping Satan in New Article 2Health News:Liver Cirrhosis Bible & Ezra Protocol Review Exposes Debra Elkin's Liver Cirrhosis Treatment Guide – Vkool - Better Information, Better Lives 2Health News:Liver Cirrhosis Bible & Ezra Protocol Review Exposes Debra Elkin's Liver Cirrhosis Treatment Guide – Vkool - Better Information, Better Lives 3Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4
... Therapy for Cardiovascular Disease (IC3D) is a three-day ... cell-based therapies for treating cardiovascular diseases. The theme ... Building Blocks: Strategies for Cardiovascular Reconstruction in 2009." ... present basic, core discussions on stem cell science ...
... our troops" is no longer just,a slogan -- it,s ... and a,new marketing campaign for the renamed Bob ... JWT Atlanta., By focusing on the physical and ... and raising money to provide,resources and support for injured ...
... for Invisicare Is Put In Place, LAS ... SKVI), the developers of Invisicare, a patented polymer,delivery ... appointment of Geert Cauwenbergh, PhD to head its ... to expand the demand,for Invisicare in international markets. ...
... HOUSTON, Nov. 6 US Oncology, Inc. ("US Oncology" ... services companies,reported revenue of $821.7 million, EBITDA of $54.5 ... million and operating cash flow,of $35.1 million for the ... ended September 30, 2008, US Oncology reported revenue of ...
... MOUNT LAUREL, N.J., Nov. 6 At ... Inc. (Nasdaq: MEDQ ) is introducing ... top-ranked,interactive front-end speech recognition application, and RadWorkFlow(R), ... RadWorkFlow offers an efficient, simplified, and ...
... LIMS System Chosen by Hospital to Replace ... Global Med Technologies(R),Inc. ("Global Med" or ... e-Health, medical information technology company, today,announced that ... Laboratory,Information Management Software (marketed as "Labo Serveur" ...
Cached Medicine News:Health News:5th Annual Global Conference on Stem Cell Therapy to be held Jan. 13-16, 2009 in NYC 2Health News:Bob Woodruff Foundation and JWT Introduce Marketing Campaign and Unveil www.ReMIND.org 2Health News:Bob Woodruff Foundation and JWT Introduce Marketing Campaign and Unveil www.ReMIND.org 3Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 2Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 3Health News:US Oncology Reports Third Quarter 2008 Results 2Health News:US Oncology Reports Third Quarter 2008 Results 3Health News:US Oncology Reports Third Quarter 2008 Results 4Health News:US Oncology Reports Third Quarter 2008 Results 5Health News:US Oncology Reports Third Quarter 2008 Results 6Health News:US Oncology Reports Third Quarter 2008 Results 7Health News:US Oncology Reports Third Quarter 2008 Results 8Health News:US Oncology Reports Third Quarter 2008 Results 9Health News:US Oncology Reports Third Quarter 2008 Results 10Health News:US Oncology Reports Third Quarter 2008 Results 11Health News:US Oncology Reports Third Quarter 2008 Results 12Health News:US Oncology Reports Third Quarter 2008 Results 13Health News:US Oncology Reports Third Quarter 2008 Results 14Health News:US Oncology Reports Third Quarter 2008 Results 15Health News:US Oncology Reports Third Quarter 2008 Results 16Health News:US Oncology Reports Third Quarter 2008 Results 17Health News:US Oncology Reports Third Quarter 2008 Results 18Health News:US Oncology Reports Third Quarter 2008 Results 19Health News:US Oncology Reports Third Quarter 2008 Results 20Health News:US Oncology Reports Third Quarter 2008 Results 21Health News:US Oncology Reports Third Quarter 2008 Results 22Health News:US Oncology Reports Third Quarter 2008 Results 23Health News:MedQuist Introduces SpeechQ for Radiology Integrated with RadWorkFlow 2Health News:MedQuist Introduces SpeechQ for Radiology Integrated with RadWorkFlow 3Health News:Global Med Technologies(R), Inc.'s Inlog Subsidiary Licenses Its Leading Laboratory Information System to Gabriel Martin Hospital of Saint-Paul de la Reunion 2Health News:Global Med Technologies(R), Inc.'s Inlog Subsidiary Licenses Its Leading Laboratory Information System to Gabriel Martin Hospital of Saint-Paul de la Reunion 3Health News:Global Med Technologies(R), Inc.'s Inlog Subsidiary Licenses Its Leading Laboratory Information System to Gabriel Martin Hospital of Saint-Paul de la Reunion 4
... are individually adjusted for perfect focus where ... on paper. This, along with Keeler's wide ... that whatever the patient's pupil size, you ... of view. Lithium-ion technology provides a longer ...
... 200 ophthalmoscope, the world's ... ophthalmoscope. Heine's aspherical optical ... along with innovative design ... the Beta 200 the ...
... The Heine Beta 200S is ... with a combination of patented ... and a range of corrective ... dpt. in single diopter steps. ...
... The ophthalmoscope with superior aspherical optics. The ... means of the aspherical optical system avoids ... 200 allows you to view the whole ... even with a small pupil. Conventional ophthalmoscopes ...
Medicine Products: